Controlling receptor pairs to explore new drug effects
Official title: A novel system for controlling dimeric receptor composition to discover unique heterodimer pharmacology
Funded at University of Rochester · NIH-11086120 · Data updated 2026-11-12
This study is looking at how certain brain receptors work together and how this affects how well drugs might help with neurological conditions, aiming to find better treatments for people who need them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | July 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $415,475 |
| NIH project number | 5R01MH125849-03 |
| Project ID | NIH-11086120 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with neurological conditions that may be influenced by metabotropic glutamate receptor activity.
✕Less likely to help
Patients with conditions unrelated to metabotropic glutamate receptors or those who do not respond to receptor-targeted therapies may not benefit from this research.
What this research studies
This research investigates how specific pairs of metabotropic glutamate receptors (mGluRs) interact and how these interactions affect drug responses. By focusing on the unique combinations of these receptors, the study aims to understand their pharmacology better, particularly in the brain where they play crucial roles in regulating excitability and plasticity. The researchers have developed a novel system to control the composition of receptor pairs, allowing for precise examination of how different receptor combinations respond to potential drug treatments. This approach could lead to more effective therapies for various neurological conditions.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that are more effective for neurological disorders.
How similar studies have gone: While the approach of examining receptor heterodimer pharmacology is relatively novel, there is a growing body of preclinical data suggesting that understanding these interactions could lead to significant advancements in treatment.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Kammermeier, Paul J. — University of Rochester
- Study coordinator: Kammermeier, Paul J.
Related research
Other NIH-funded projects on the same topics.
-
Rapid automated breast lump diagnosis without a radiologist or sonographer
A new AI-powered ultrasound tool helps determine if a palpable breast lump is likely benign or malignant, using a simplified technique that can be used by people with minimal ultrasound training.
-
ML-ROVER: Reducing Unneeded Lab Tests in Kids with AI
Aims to use machine learning to cut unnecessary blood tests in children in intensive care, helping avoid anemia and improve care quality.
-
Aggressive fever-reducing therapy to protect the brains of children with CNS malaria
A study planned for children with CNS malaria will test whether aggressive fever-reducing treatment can lower death and brain-related problems.
-
Aggressive fever-reducing therapy to protect brains in children with CNS malaria
A plan to test whether giving strong fever-reducing medications to children with central nervous system malaria can lower death and brain injury.
-
Aggressive fever-fighting treatment to protect the brain in kids with CNS malaria
A plan to test whether giving strong fever-reducing treatment alongside standard care can lower death and brain injury in children with CNS malaria.
-
Aggressive fever-reducing treatment to protect brains in kids with CNS malaria
A plan to test whether giving strong fever-reducing medicine alongside standard malaria treatment can lower deaths and brain injuries in children with CNS malaria.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.